Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions

被引：35
作者：
Alagoz, O. [1 ]
Durham, D. [2 ]
Kasirajan, K. [3 ]
机构：
[1] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI USA
[2] Sage Neurosci Ctr, Dept Psychiat, Albuquerque, NM USA
[3] Ally Clin Diagnost, Dallas, TX USA
来源：
PHARMACOGENOMICS JOURNAL | 2016年 / 16卷 / 02期
关键词：
HOSPITALIZED-PATIENTS; ANTIPLATELET THERAPY; UNITED-STATES; EVENTS;
D O I：
10.1038/tpj.2015.39
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
We evaluated the cost-effectiveness of one-time pharmacogenomic testing for preventing adverse drug reactions (ADRs) over a patient's lifetime. We developed a Markov-based Monte Carlo microsimulation model to represent the ADR events in the lifetime of each patient. The base-case considered a 40-year-old patient. We measured health outcomes in life years (LYs) and quality-adjusted LYs (QALYs) and estimated costs using 2013 US$. In the base-case, one-time genetic testing had an incremental cost-effectiveness ratio (ICER) of $43 165 (95% confidence interval (CI) is ($42 769,$43 561)) per additional LY and $53 680 per additional QALY (95% CI is ($53 182,$54 179)), hence under the base-case one-time genetic testing is cost-effective. The ICER values were most sensitive to the average probability of death due to ADR, reduction in ADR rate due to genetic testing, mean ADR rate and cost of genetic testing.
引用
收藏
页码：129 / 136
页数：8
相关论文
共 27 条
[1]  
Agency for Healthcare Research and Quality, 2011, EM ROOM SERV MEAN ME
[2]   Markov Decision Processes: A Tool for Sequential Decision Making under Uncertainty [J].
Alagoz, Oguzhan ;
Hsu, Heather ;
Schaefer, Andrew J. ;
Roberts, Mark S. .
MEDICAL DECISION MAKING, 2010, 30 (04) :474-483
[3]   Adverse drug reactions in United States hospitals [J].
Bond, CA ;
Raehl, CL .
PHARMACOTHERAPY, 2006, 26 (05) :601-608
[4]   Adverse drug events in the outpatient setting: an 11-year national analysis [J].
Bourgeois, Florence T. ;
Shannon, Michael W. ;
Valim, Clarissa ;
Mandl, Kenneth D. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (09) :901-910
[5]   National surveillance of emergency department visits for outpatient adverse drug events [J].
Budnitz, Daniel S. ;
Pollock, Daniel A. ;
Weidenbach, Kelly N. ;
Mendelsohn, Aaron B. ;
Schroeder, Thomas J. ;
Annest, Joseph L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (15) :1858-1866
[6]   Emergency Hospitalizations for Adverse Drug Events in Older Americans [J].
Budnitz, Daniel S. ;
Lovegrove, Maribeth C. ;
Shehab, Nadine ;
Richards, Chesley L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (21) :2002-2012
[7]  
Centers for Disease Control Prevention, 2013, CDC NCHS NAT HOSP DI
[8]   Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness [J].
Chou, WH ;
Yan, FX ;
de Leon, J ;
Barnhill, J ;
Rogers, T ;
Cronin, M ;
Pho, M ;
Xiao, V ;
Ryder, TB ;
Liu, WW ;
Teiling, C ;
Wedlund, PJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) :246-251
[9]   How many deaths occur annually from adverse drug reactions in the United States? [J].
Chyka, PA .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (02) :122-130
[10]   Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality [J].
Classen, DC ;
Pestotnik, SL ;
Evans, RS ;
Lloyd, JF ;
Burke, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :301-306
123